Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 581-588

  Karpoff, Howard M ^a   Kooby, David ^a   D'Angelica, Michael ^a   Mack, Jonathan ^a   Presky, David H ^b   Brownlee, Michael D ^c   Federoff, Howard ^d   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Herpes simplex virus; Interleukin; Interleukin 12; Interleukin 2; Liver; Tumor vaccine

Indexed keywords

CANCER VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ANIMALIA; DNA VIRUSES; HERPES; SIMPLEXVIRUS;

EID: 0034033064     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700135     Document Type: Article

References (51)

1. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
2. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
3. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 1993;53:714-716.
4. Karpoff HM, D'Angelica M, Blair S, Brownlee MD, Federoff H, Fong Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and γ-interferon. J Clin Invest. 1997;99:799-804.
5. Pardoll DM. Genetically engineered tumor vaccines. Ann N Y Acad Sci. 1993;690:301-310.
6. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-A genes. J Immunother. 1993; 14:191-201.
7. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
8. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 1996;156:3357-3365.
9. Brunda MJ. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
10. Pappo I, Tahara H, Robbins PD, et al. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res. 1995;58: 218-226.
11. Chang L, Bruner V, van de Ven C, Cairo MS. Synergistic enhancement of natural killer (NK) cell activity with cord blood by IL2 + IL12: a future immunotherapy approach post cord BMT. Proc Annu Meet Am Assoc Cancer Res. 1995;36:466. Abstract A2773.
12. Vagliani M, Rodolfo M, Cavallo F, et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin-2-transduced tumor cells. Cancer Res. 1996;56: 467-470.
13. Kutteh WH, Rainey WE, Carr BR. Regulation of interleukin-6 production in human fetal Kupffer cells. Scand J Immunol. 1991;33:607-613.
14. West MA, Keller GA, Xerra FB, Simmons RL. Killed Escherichia coli stimulates macrophage-mediated alterations in hepatocellular function during in vitro coculture: a mechanism of altered liver function in sepsis. Infect Immun. 1985;49:563-569.
15. Karpoff HM, Tung C, Ng B, Fong Y. γ-interferon protects against hepatic tumor growth in rats by increasing Kupffer cell tumoricidal activity. Hepatology. 1996;24:374-379.
16. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA. 1990;87:8950-8954.
17. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science. 1988;241:1667-1669.
18. Federoff JH. Growth of replication-defective herpes virus amplicon vectors and their use for gene transfer. In: Spector DL, Leinwand L, Goldman R, eds. Cell Biology: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Laboratory Press; 1996.
19. Bergold P, Cassaccia-Bonnefil P, Xiu-Liu Z, Federoff H. Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor. Proc Natl Acad Sci USA. 1993;90:6165-6169.
20. Linnik M, Zahos P, Geschwind M, Federoff H. Expression of bc1-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke. 1995;26:1670-1675.
21. Xu H, Federoff H, Maragos J, Parada LF, Kessler J. Viral transduction of trk A into cultured nodose and spinal motor neurons conveys NGF responsiveness. Dev Biol. 1994;163:152-161.
22. Johnson P, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type I. J Virol. 1992;66:2952-2965.
23. Paterson T, Everett RA. A prominent serine-rich region in Vmw175, the major transcriptional regulator protein of herpes simplex virus type 1, is not essential for virus growth in tissue culture. J Gen Virol. 1990;71:1775-1783.
24. Expression of neurotrophic genes from herpes simplex virus type I vectors modifying neuronal phenotype. In: Geschwind M, Lu B, Federoff HJ, Flanagan TR, Emerich DF, Winn SR, eds. Providing Pharmacological Access to the Brain: Alternative Approaches. New York: Academic Press; 1994;462-482.
25. Gately MK, Chizzonite R, Presky DH. Measurement of Human and Mouse Interleukin 12. New York: John Wiley & Sons; 1995;1:6.16.1-6.16.15.
26. Tung C, Federoff HJ, Brownlee M, et al. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Therapy. 1996;7:2217-2224.
27. Rosenberg SA. Adoptive immunotherapy for cancer. Sci Am. 1990;262:34-39.
28. Ley V, Langlade-Demoyen P, Kourilsky P, Larrson-Sciard E. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol. 1991;21: 851-854.
29. Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest. 1993;11:460-472.
30. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
31. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med. 1993; 177:1127-1134.
32. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene-modified tumor vaccines. Cancer Res. 1994; 54:1760-1765.
33. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
34. Myers JN, Mank-Seymour A, Zitvogel L, et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope. 1998;108:261-268. Abstract.
35. Matsumoto G, Sunamura M, Shimamura H, et al. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Surgery. 1999;125:257-264. Abstract.
36. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474. Abstract.
37. Ahuja SS, Mummidi S, Malech HL, et al. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-γ and IL-12. J Immunol. 1998;161: 868-876. Abstract.
38. Chen L, Chen D, Block E, et al. Eradication of murine bladder carcinoma by intratumor injection of bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997;159:351-359. Abstract.
39. Bramson JL, Hitt M, Gallichan WS, et al. Construction of double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7: 333-342. Abstract.
40. Hemmi S, Geertsen R, Mezzacassa A, et al. The presence of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 1998;9:2363-2373. Abstract.
41. Bruna MJ, Lusitro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med. 1993;178:1223-1230.
42. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
43. Ye J, Ortaldo JR, Conlon K, et al. Cellular and molecular mechanisms of IFN-γ production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol. 1995;58:225-233. Abstract.
44. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood. 1994; 83:1323-1328.
45. DeBlacker-Hohe DF, Yamauchi A, Yu CR, et al. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perform and granzyme gene expression in fresh human NK cells. Cell Immunol. 1995;165:33-43. Abstract.
46. Mogi S, Ebata T, Setoguchi Y, et al. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2. Clin Cancer Res. 1998;4:713-720.
47. Rashleigh SP, Kusher DI, Endicott JN, et al. Interleukins 2 and 12 activate natural killer cytolytic responses of peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1996;122:541-547. Abstract.
48. Kikuchi T, Joki T, Saitoh S, et al. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer. 1999;80:425-430. Abstract.
49. Wigginton JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst. 1996;88:38-43. Abstract.
50. Schuurman B, Heuff G, Beelan RH, Meyer S. Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony stimulating factor and interferon γ. Cancer Immunol Immunother. 1994;39: 179-184.
51. Raper SE, Grossman M, Rader DJ, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg. 1996; 223:116-126.